You are here

Merck

Incyte study could bring lessons for cancer immunotherapy

Biopharma Dive

Wed, 03/14/18 - 11:27 am

cancer immunotherapy

metastatic melanoma

[video]How Convenience Can Give Drugmakers a Competitive Edge

Motley Fool

Tue, 03/13/18 - 10:08 am

Bristol-Myers Squibb

Merck C.E.O. Ken Frazier on Death Row Cases and the Corporate Soul

NY Times, NY

Sat, 03/10/18 - 09:14 am

Kenneth Frazier

Doubling down on the Keytruda franchise, Merck pays $300M and promises $5B-plus to partner with Eisai on its budding cancer star

Endpoints

Thu, 03/8/18 - 09:42 am

Senator questions big pharma buyback strategy

Biopharma Dive

Tue, 03/6/18 - 09:30 am

share repurchase

Analyzing the strategy by Ken Frazier, Merck & Co CEO

GoinPharma

Sun, 02/25/18 - 11:12 am

Merck’s melanoma drug shows early promise for resistant cancers in PhI trial

Endpoints

Sat, 02/24/18 - 10:21 am

clinical trials

Gilead wins reprieve in Merck's $2.5B patent lawsuit

Biopharma Dive

Thu, 02/22/18 - 09:52 am

Gilead Sciences

Merck to buy virus-based cancer drug firm Viralytics for $394 million

Reuters

Wed, 02/21/18 - 11:04 pm

The C.E.O. Who Stood Up to President Trump: Ken Frazier Speaks Out

NY Times, NY

Tue, 02/20/18 - 10:40 pm

Kenneth Frazier

Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict

Reuters

Sun, 02/18/18 - 10:10 am

Gilead Sciences

White House: Merck and others hit by NotPetya were collateral damage in Russia’s cyberwar on the Ukraine

Endpoints

Sun, 02/18/18 - 10:08 am

Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst

Fierce Pharma

Fri, 02/16/18 - 09:29 pm

Merck scraps another late-stage Alzheimer's drug study

Yahoo/Reuters

Wed, 02/14/18 - 11:55 pm

Alzheimer's disease

Merck says Keytruda's explosive growth prompts need for new Ireland plant with 350 jobs

Fierce Pharma

Wed, 02/14/18 - 11:33 am

drug manufacturing

Senior Merck chemist charged with risking catastrophe after pouring cyanide into Pennsylvania stormwater drain

Endpoints

Wed, 02/14/18 - 11:32 am

Merck just dashed the last remaining hopes for its industry-leading BACE drug for Alzheimer’s

Endpoints

Tue, 02/13/18 - 11:14 pm

BACE inhibitors

Alzheimer's disease

Gardasil grows, Zostavax struggles as Merck posts $6.5B in 2017 vaccine sales

Fierce Pharma

Tue, 02/6/18 - 08:38 pm

Biopharma in charts: Key takeaways from Q4 earnings

Biopharma Dive

Mon, 02/5/18 - 12:35 pm

3 Headwinds in Q4 Earnings Results That Make Merck a Mediocre Stock

Motley Fool

Sun, 02/4/18 - 11:44 am

cardiovascular disease

Pages